Skip to content

US · NAGE · BIOTECHNOLOGY

Niagen Bioscience Inc (NAGE) intrinsic value and stock valuation

$1.84as of 2026-11-21 · Mkt cap 235.75M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Niagen Bioscience Inc DCF and intrinsic value

InvestorsCraft values NAGE with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NAGE’s statements →

Niagen Bioscience Inc Graham Number

Graham Number: $2.18d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Los Angeles, CA 90024 niagenbioscience.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$129.4M+16.9% 5y CAGRd
20112025
Net income
$17.4M
20112025
Free cash flow
$13.1M
20112025
Total equity
$76.5M+36% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$129.4M$99.6M$83.6M$72.1M$67.5M
Operating income$14.3M$7.73M-$-5.6M-$-18.63M-$-27.07M
Net income$17.4M$8.55M-$-4.94M-$-16.54M-$-27.13M
EPSd$203.4K$107.3K-$-65.88K-$-237.2K-$-403.78K
Operating cash flow$13.4M$12.1M$7.12M-$-15.1M-$-24.16M
Capital expenditure-$-290K-$-160K-$-150K-$-330K-$-410K
Free cash flow$13.1M$12M$6.97M-$-15.43M-$-24.57M
Total assets$106.4M$68.3M$55M$54.1M$57.8M
Total debt$2.82M$2.65M$3.28M$4.26M$4.7M
Net debt-$-61.97M-$-41.86M-$-23.9M-$-16.03M-$-23.32M
Total equity$76.5M$46.1M$28.5M$28.7M$31.7M
Cash and short-term investments$64.8M$44.5M$27.2M$20.3M$28M
Income statement
20252024202320222021
Revenue$129.4M$99.6M$83.6M$72.1M$67.5M
Cost of revenue$46.2M$38M$32.8M$29.3M$26M
Gross profit$83.2M$61.6M$50.8M$42.8M$41.5M
Research and development expenses$6.33M$6.02M$4.96M$4.83M$3.83M
Selling, general and administrative expenses$62.6M$47.8M$51.4M$56.6M$64.7M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$68.9M$53.9M$56.4M$61.4M$68.6M
Cost and expenses$115.1M$91.9M$89.2M$90.7M$94.5M
Interest income$2.13M$1.13M$660K$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$60K
Depreciation and amortization$1.45M$1.48M$1.71M$1.88M$1.63M
Ebitda$19.6M$10.3M-$-3.23M-$-14.66M-$-25.45M
Operating income$14.3M$7.73M-$-5.6M-$-18.63M-$-27.07M
Total other income/expenses, net$3.9M$1.13M$660K$2.09M-$-60K
Income before tax$18.2M$8.86M-$-4.94M-$-16.54M-$-27.13M
Income tax expense$810K$300K$0.00$0.00$0.00
Net income$17.4M$8.55M-$-4.94M-$-16.54M-$-27.13M
Weighted average shares outstanding$79.2M$85.4M$70.5M$68.9M$67.2M
Weighted average diluted shares outstanding$85.4M$79.7M$75M$69.7M$67.2M
Balance sheet
20252024202320222021
Cash and short-term investments$64.8M$44.5M$27.2M$20.3M$28M
Net receivables$9.74M$7.77M$5.23M$8.48M$5.23M
Inventory$20.4M$9.19M$14.5M$14.7M$13.6M
Total current assets$96.8M$64.1M$49.5M$46.6M$48.9M
Property, plant and equipment, net$3.52M$3.45M$4.54M$6.32M$7.36M
Goodwill and intangible assets$5.66M$360K$510K$670K$860K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$9.6M$4.18M$5.43M$7.49M$8.94M
Total assets$106.4M$68.3M$55M$54.1M$57.8M
Accounts payable$10.8M$8.53M$10.2M$9.68M$10.4M
Short-term debt$1M$990K$700K$700K$550K
Deferred revenue$0.00$610K$200K$160K$160K
Total current liabilities$19.9M$18M$20.6M$17.9M$17.6M
Long-term debt$1.81M$1.66M$2.58M$3.56M$4.15M
Deferred revenue, non-current$2.67M$2.58M$3.31M$3.96M$4.35M
Total non-current liabilities$9.95M$4.24M$5.89M$7.52M$8.5M
Capital lease obligations$1.81M$2.65M$3.28M$4.26M$4.7M
Total liabilities$29.9M$22.2M$26.5M$25.4M$26.1M
Common stock$80K$80K$70K$70K$70K
Retained earnings-$-164.53M-$-181.91M-$-190.46M-$-185.49M-$-168.95M
Accumulated other comprehensive income (loss)-$-10K-$0.00-$0.00-$0.00-$0.00
Total equity$76.5M$46.1M$28.5M$28.7M$31.7M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$2.82M$2.65M$3.28M$4.26M$4.7M
Net debt-$-61.97M-$-41.86M-$-23.9M-$-16.03M-$-23.32M
Cash flow statement
20252024202320222021
Net income$17.4M$8.55M-$-4.94M-$-16.54M-$-27.13M
Depreciation and amortization$1.45M$1.48M$1.71M$1.88M$1.63M
Stock-based compensation$6.07M$3.66M$4.75M$5.74M$6.2M
Change in working capital-$-8.3M$3.13M$4.62M-$-6.01M-$-4.73M
Accounts receivable-$-760K-$-1.28M$2.25M-$-3.32M-$-2.58M
Inventory-$-11.63M$5.33M$150K-$-1.08M-$-1.92M
Accounts payable$2.27M-$-1.07M$550K-$-740K$980K
Net cash provided by operating activities$13.4M$12.1M$7.12M-$-15.1M-$-24.16M
Investments in property, plant and equipment-$-290K-$-160K-$-150K-$-330K-$-410K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-290K-$-140K-$-140K-$-330K-$-410K
Common stock issued$7.25M$5.43M$0.00$7.75M$26.7M
Common stock repurchased-$-250K$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$6.98M$5.37M-$-90K$7.65M$36.1M
Net change in cash$20.1M$17.3M$6.88M-$-7.78M$11.5M
Cash at end of period$64.8M$44.7M$27.3M$20.4M$28.2M
Operating cash flow$13.4M$12.1M$7.12M-$-15.1M-$-24.16M
Capital expenditure-$-290K-$-160K-$-150K-$-330K-$-410K
Free cash flow$13.1M$12M$6.97M-$-15.43M-$-24.57M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Niagen Bioscience Inc

        Niagen Bioscience Inc operates as a biotechnology enterprise with a core focus on promoting healthy aging. This company is also renowned for its pioneering research into nicotinamide adenine dinucleotide.

        CEO
        Robert N. Fried
        Employees
        117
        Beta
        2.08

        Explore

        Frequently asked questions

        What is the intrinsic value of Niagen Bioscience Inc (NAGE)?

        InvestorsCraft does not currently publish an intrinsic value for NAGE. How the IC value is calculated.

        Is NAGE undervalued?

        InvestorsCraft does not publish an undervaluation signal for NAGE at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.